文献速递临床试验与 GCP基础与转化研究

自体脂肪组织来源干细胞移植治疗衰老相关低度炎症患者的安全性与疗效:单组、开放标签、I期临床试验

Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial.
PubMed 文献 · Trials · 2024-05-08

本研究为单组、开放标签、I期临床试验,纳入12例同时具有高促炎细胞因子及糖尿病、血脂异常、肥胖中至少2种的衰老相关低度炎症患者,接受2次自体脂肪组织来源间充质干细胞静脉输注(每次1亿细胞)。随访期间未观察到不良事件,第180天促炎细胞因子IL-1α、IL-1β、IL-8、IL-6、TNF-α较基线显著降低,抗炎/促炎比值失衡得到逆转。

要点

  • 12例衰老相关低度炎症患者接受2次自体AD-MSC静脉输注,每次1亿细胞。
  • 随访期间未观察到不良事件。
  • 第180天促炎细胞因子较基线显著降低,抗炎/促炎比值失衡逆转。

核心结论

  • 自体脂肪组织来源间充质干细胞可能是预防患者衰老相关炎症的潜在干预手段。

研究设计与样本

  • 单组、开放标签、I期临床试验,纳入12例衰老相关低度炎症患者,同时具有高促炎细胞因子及糖尿病、血脂异常、肥胖中至少2种疾病。
  • 患者接受2次自体AD-MSC静脉输注,每次1亿细胞。
  • 治疗效应基于血浆细胞因子评估,随访至第180天。

主要发现

  • 随访期间AD-MSC输注患者未观察到不良事件。
  • 与基线(D-44)相比,MSC输注后第180天(D180)促炎细胞因子IL-1α、IL-1β、IL-8、IL-6、TNF-α显著降低。
  • 第90天(D90)IL-4/IL-10及第180天(D180)IL-2/IL-10升高,逆转了患者促炎与抗炎比值失衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflamm-aging is associated with the rate of aging and is significantly related to diseases such as Alzheimer's disease, Parkinson's disease, atherosclerosis, heart disease, and age-related degenerative diseases such as type II diabetes and osteoporosis. This study aims to evaluate the safety and efficiency of autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation in aging-related low-grade inflammation patients. METHODS: This study is a single-group, open-label, phase I clinical trial in which patients treated with 2 infusions (100 million cells i.v) of autologous AD-MSCs were initially evaluated in 12 inflamm-aging patients who concurrently had highly proinflammatory cytokines and 2 of the following 3 diseases: diabetes, dyslipidemia, and obesity. The treatment effects were evaluated based on plasma cytokines. RESULTS: During the study's follow-up period, no adverse effects were observed in AD-MSC injection patients. Compared to baseline (D-44), the inflammatory cytokines IL-1α, IL-1β, IL-8, IL-6, and TNF-α were significantly reduced after 180 days (D180) of MSC infusion. IL-4/IL-10 at 90 days (D90) and IL-2/IL-10 at D180 increased, reversing the imbalance between proinflammatory and inflammatory ratios in the patients. CONCLUSION: AD-MSCs represent a potential intervention to prevent age-related inflammation in patients. TRIAL REGISTRATION: ClinicalTrials.gov number is NCT05827757, first registered on 13th Oct 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nguyen NT, Phan HT, Le PM, et al. Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial. Trials. 2024. PMID: 38715140. doi:10.1186/s13063-024-08128-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。